2018 Associate Sponsors


2018 Media Partners

Life Science Leader
SciDoc Publishers
Technology Networks

2017 Executive Sponsors

Foundation Medicine
Mitra Biotech

2017 Associate Sponsors

Adaptive Biotechnologies
SignalRX Pharmaceuticals

2017 Educational Partners


2017 Media Partners

BioPharm Insight
BioPharma Dive
Clinical Leader
Life Science Leader
Pharmaceutical Online
SciDoc Publishers
Technology Networks

2017 Featured Speakers

Industry and Academic Leaders Address Scientific, Clinical and Business Developments in IO Combination Strategies to Fight a Wider Range of Cancers

” The aim is to create transformational medicines, with bigger effects for mono-therapies or combinations” ~ Dr Axel Hoos, SVP, Oncology R&D, GSK


Lead advisors Dr Patrick Hwu, MD Anderson, Dr Ian McCaffery, Corvus Pharmaceuticals and Dr Axel Hoos, GSK, presented the 2nd annual Rational Combinations 360° program that addressed business aspects, clinical advancements and scientific data in IO combination strategies to fight a wider range of cancers.

Understanding and determining how to apply certain IO combinations for the right patients and specific tumor types is arguably the most difficult challenge within cancer immunotherapy.

Rational Combinations 360° provided the most up-to-date research, data and progress on combination developments to help IO stakeholders:

  • Be at the forefront of the most relevant research and developments for IO combinations from key leadership who are at the pulse of cancer immunotherapy
  • Better understand what assets are available for potential combinations that may be able to give patients more treatment options
  • Create and prioritize combination strategies targeted toward specific tumor types
  • Foster collaboration amongst others working in all aspects of cancer immunotherapy by rounding up all stakeholders under one roof

The Rational Combinations 360° event concentrated on the following key areas:

  • Derisking of Combination Immunotherapies
  • Clinical Combination Immunotherapies
  • Immuno Resistance – Drivers for Combination Therapy
  • Novel Technologies and Emerging Biomarkers
  • Clinical Manifestations of Immunological Toxicities
  • Business Aspects for Combination Immunotherapy





Kate Woda
Conference Director

Valerie Bowling New



Valerie Bowling
Executive Director



Meredith Sands
Executive Director, Business Development

Elizabeth Bard B&W-47



Elizabeth Bard
Business Development Manager




Geeta Bachani
Business Development Manager




Nancy Belis
Senior Conference Planner




  • "I absolutely enjoyed the meeting! It was great getting both academia and industry together to discuss how we move forward."

    - Robert Andtbacka, Huntsman Cancer Institute

  • "Thanks so much for putting on a great conference. It was very informative and I was excited to be a part of it. I am looking forward to the next one!"

    - Amanda Bruno, GSK

  • "It was a great conference. I learned a lot and enjoyed the diversity of speakers"

    - Julia Keith, RA Capital

  • "It was great meeting. I really enjoyed the conference and my interactions with several of the participants."

    - Jeffrey Wallin, Genentech